Does Praluent Lower Cholesterol?
Yes, Praluent (alirocumab) lowers LDL cholesterol, often called "bad" cholesterol. The FDA approved it in 2015 for adults with high cholesterol not adequately controlled by statins, either alone or combined with other treatments. Clinical trials showed it reduces LDL-C by 47-61% on average when added to statins, with effects starting within 4 weeks.[1][2]
How Does Praluent Work?
Praluent is a PCSK9 inhibitor given as a subcutaneous injection every 2 or 4 weeks. It blocks PCSK9 protein, which normally degrades LDL receptors in the liver. More receptors mean the liver pulls more LDL from the blood, lowering circulating levels.[1]
Who Gets Prescribed Praluent?
It's for:
- Patients with heterozygous familial hypercholesterolemia (HeFH).
- Those with atherosclerotic cardiovascular disease (ASCVD) needing extra LDL reduction.
- Adults on maximally tolerated statins with LDL-C ≥70 mg/dL.
Dosing starts at 75 mg every 2 weeks, adjustable to 150 mg if needed.[1][2]
Clinical Trial Results on Cholesterol Reduction
Key studies (ODYSSEY program):
- ODYSSEY COMBO I: 58% LDL reduction vs. placebo.
- ODYSSEY LONG TERM: 58% reduction; also cut major CV events by 48% (not primary endpoint).
- FOURIER (similar drug evolocumab): Confirmed class effect with 59% LDL drop.
Real-world data aligns, with reductions of 50-60% in high-risk patients.[2][3]
Does It Reduce Heart Attack or Stroke Risk?
Praluent lowers LDL but primary trials focused on lipids, not always hard CV outcomes. ODYSSEY OUTCOMES (17,000+ post-heart attack patients) showed 15% relative risk reduction in major CV events, driven by fewer deaths and MI.[3]
Common Side Effects and Risks
Injection-site reactions (7%), nasopharyngitis, and flu-like symptoms occur most. Rare: Allergic reactions, neurocognitive effects. No liver toxicity signal unlike statins. Monitor for hypersensitivity.[1][2]
How Does Praluent Compare to Other Cholesterol Drugs?
| Drug | Class | LDL Reduction | Dosing | Key Difference |
|------|--------|---------------|--------|---------------|
| Praluent | PCSK9 inhibitor | 50-60% | Injection q2-4w | Targets PCSK9; expensive |
| Repatha (evolocumab) | PCSK9 inhibitor | 55-65% | Injection q2-4w | Similar efficacy; FOURIER showed CV benefit |
| Rosuvastatin (Crestor) | Statin | 40-55% | Daily pill | Cheaper; muscle pain risk |
| Inclisiran (Leqvio) | siRNA | 50-55% | Injection q6mo | Less frequent dosing |
Praluent outperforms statins alone but costs $5,000-14,000/year without insurance.[2][4]
Cost, Access, and Patent Status
List price ~$5,850/month, but copay cards drop patient costs to $5-25. Patents expire around 2031-2033 in the US; check DrugPatentWatch.com for updates on challenges or generics.[4][5]
[1]: FDA Label - Praluent (alirocumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125559s028lbl.pdf
[2]: NEJM - ODYSSEY Trials. https://www.nejm.org/doi/full/10.1056/NEJMoa1610716
[3]: NEJM - ODYSSEY OUTCOMES. https://www.nejm.org/doi/full/10.1056/NEJMoa1801174
[4]: GoodRx - Praluent Pricing. https://www.goodrx.com/praluent
[5]: DrugPatentWatch - Praluent Patents. https://www.drugpatentwatch.com/p/tradename/PRALUENT